Your session is about to expire
← Back to Search
Batiraxcept + Paclitaxel for Uterine Cancer
Study Summary
This trial tests a new drug for advanced uterine cancer. It includes a dose escalation and expansion phase, plus biopsy and metabolism testing. To identify potential response biomarkers, immunohistochemistry will be used.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have cancer that has spread to my brain.I have previously been treated with AVB-500.My blood tests for bone marrow and organ function are normal.My kidney function is within the required range.I have a wound, ulcer, or bone fracture that hasn’t healed.I do not have a history of serious heart conditions.I had cancer within the last 2 years but now show no signs of it.I have a history of or currently have a brain or spinal cord condition.My cancer has returned, is high-grade, and didn't respond well to platinum-based treatment.I have received targeted therapy for my dMMR, MSI-H, or HER2-altered tumor.My condition cannot be treated with surgery or radiation alone.I can take care of myself but might not be able to do heavy physical work.I have had severe gastrointestinal issues in the last 3 months.I have not had major surgery in the last 14 days.I have been treated with trastuzumab, pembrolizumab, or dostarlimab.I do not have an active hepatitis or ongoing serious infection.I haven't had chemotherapy, radiation, or immunotherapy in the last 4 weeks.I am a woman or a transgender man over 18 with a uterus.I do not have any uncontrolled illnesses.
- Group 1: Paclitaxel + AVB-500
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
To what degree of risk is the combination of Paclitaxel and AVB-500 exposing patients?
"Paclitaxel + AVB-500's safety rating is a 1, as this trial is in its first phase and thus the data supporting both efficacy and safety are limited."
Does this trial currently have vacancies for potential participants?
"The clinicaltrials.gov page for this trial reveals that it is not looking for new participants; the study was first made public on July 31st 2023, and its last update came April 11th of the same year. However, there are still 1086 other experiments in need of volunteers at present."
To what extent is this research project being conducted in hospitals?
"Four medical centres are running this clinical trial, with the Washington University School of Medicine in Saint Louis, New mexico's University of Albuquerque and Oklahoma City's University of Oklahoma as some major sites. In addition to these three locations there is also recruitment at four other institutions."
Share this study with friends
Copy Link
Messenger